CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
vorinostatdrug
Likely dose
Vorinostat 100 mg, 200 mg, 400 mg, or 500 mg orally, once-daily or twice-daily (dose-escalation study)AI-extracted
Key inclusion· 1
  • ✓Histologically or cytologically confirmed solid tumor with no available standard therapy or prior failure of standard therapy
Key exclusion· 5
  • ✕Any immunotherapy, radiotherapy, surgery, or chemotherapy within the previous 4 weeks
  • ✕5 or more prior chemotherapy regimens
  • ✕Uncontrolled concomitant illness
  • ✕Pregnancy or breast-feeding

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00127127
NCT00127127Phase 1Completed
CompareCT.gov

A Phase I Clinical Study of L-001079038 in Patients With Solid Tumors

Merck Sharp & Dohme LLC·interventional·Posted Aug 5, 2005·Updated Sep 13, 2022

In Brief

A Phase 1 clinical trial evaluating vorinostat for Tumors. Completed, enrolled 18 participants.

Detailed Summary

The primary purpose of this trial is to determine the maximum tolerated dose (MTD), or the maximum acceptable dose (MAD) and evaluate the dose limiting toxicity (DLT) of oral suberoylanilide hydroxamic acid in participants with solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTumors
Countries--
Collaborators--

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 5, 2005
Enrollment StartJun 10, 2005
Primary CompletionAug 21, 2009
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 20.9 years ago

Interventions

vorinostatdrug

vorinostat 100 mg, 200 mg, 400 mg, or 500 mg single oral dose; once-daily or twice-daily administration